These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31202792)

  • 1. Practically scheduling hormone therapy for prostate cancer using a mathematical model.
    Nakanishi A; Hirata Y
    J Theor Biol; 2019 Oct; 478():48-57. PubMed ID: 31202792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer.
    Hirata Y; Azuma S; Aihara K
    Methods; 2014 Jun; 67(3):278-81. PubMed ID: 24680737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer.
    Voth AM; Alford JG; Swim EW
    Math Biosci Eng; 2017 Jun; 14(3):777-804. PubMed ID: 28092963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.
    Suzuki Y; Sakai D; Nomura T; Hirata Y; Aihara K
    J Theor Biol; 2014 Jun; 350():1-16. PubMed ID: 24524858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression.
    Yang J; Zhao TJ; Yuan CQ; Xie JH; Hao FF
    J Theor Biol; 2016 Sep; 404():66-72. PubMed ID: 27259386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.
    Hirata Y; Morino K; Akakura K; Higano CS; Aihara K
    Sci Rep; 2018 Feb; 8(1):2673. PubMed ID: 29422657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between mathematical models of intermittent androgen suppression for prostate cancer.
    Hatano T; Hirata Y; Suzuki H; Aihara K
    J Theor Biol; 2015 Feb; 366():33-45. PubMed ID: 25451517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy.
    Suzuki T; Aihara K
    Math Biosci; 2013 Sep; 245(1):40-8. PubMed ID: 23648278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematically modelling and controlling prostate cancer under intermittent hormone therapy.
    Hirata Y; Tanaka G; Bruchovsky N; Aihara K
    Asian J Androl; 2012 Mar; 14(2):270-7. PubMed ID: 22231293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer.
    Suzuki T; Bruchovsky N; Aihara K
    Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5045-59. PubMed ID: 20921011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer.
    Hirata Y; Bruchovsky N; Aihara K
    J Theor Biol; 2010 May; 264(2):517-27. PubMed ID: 20176032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A partial differential equation model and its reduction to an ordinary differential equation model for prostate tumor growth under intermittent hormone therapy.
    Tao Y; Guo Q; Aihara K
    J Math Biol; 2014 Oct; 69(4):817-38. PubMed ID: 23982260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent androgen suppression for prostate cancer.
    Buchan NC; Goldenberg SL
    Nat Rev Urol; 2010 Oct; 7(10):552-60. PubMed ID: 20842189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
    Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
    Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy.
    Hirata Y; Morino K; Akakura K; Higano CS; Bruchovsky N; Gambol T; Hall S; Tanaka G; Aihara K
    PLoS One; 2015; 10(6):e0130372. PubMed ID: 26107379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
    Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
    Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical modelling of prostate cancer growth and its application to hormone therapy.
    Tanaka G; Hirata Y; Goldenberg SL; Bruchovsky N; Aihara K
    Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5029-44. PubMed ID: 20921010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer.
    Shimada T; Aihara K
    Math Biosci; 2008; 214(1-2):134-9. PubMed ID: 18420226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.